Pharmacology of erectile dysfunction in man

被引:38
作者
Cirino, Giuseppe
Fusco, Ferdinando
Imbirabo, Ciro
Mirone, Vincenzo
机构
[1] Dipartimento Farmacol Sperimentale, I-8031 Naples, Italy
[2] CIRMS, Naples, Italy
关键词
erectile dysfunction; risk factors; peripheral mechanisms; human preclinical and clinical; PDE5; peripheral regulation;
D O I
10.1016/j.pharmthera.2005.10.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual activity (2nd International Consultation on Sexual Dysfunction-Paris, June 28th-July 1st, 2003). Following the discovery and introduction of sildenafil, research on the mechanisms underlying penile erection has had an enormous boost and many preclinical and clinical papers have been published in the last 5 years. This review is structured in order to give the reader an over-view of the clinical and preclinical data available on the peripheral regulation of and the mediators involved in human penile erection. The most widely accepted risk factors for ED are discussed. The article is focused on human data, and the safety and effectiveness of the 3 commercially available Phosphodiesterase-5 (PDE5) inhibitors used to treat ED are also discussed. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:400 / 423
页数:24
相关论文
共 181 条
[21]   DYSFUNCTIONAL PENILE CHOLINERGIC NERVES IN DIABETIC IMPOTENT MEN [J].
BLANCO, R ;
DETEJADA, IS ;
GOLDSTEIN, I ;
KRANE, RJ ;
WOTIZ, HH ;
COHEN, RA .
JOURNAL OF UROLOGY, 1990, 144 (02) :278-280
[22]   Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum [J].
Bloch, W ;
Klotz, T ;
Sedlaczek, P ;
Zumbe, J ;
Engelmann, U ;
Addicks, K .
UROLOGICAL RESEARCH, 1998, 26 (02) :129-135
[23]  
Blumentals W A, 2003, Aging Male, V6, P217, DOI 10.1080/13685530312331309752
[24]   Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study [J].
Blumentals, WA ;
Gomez-Caminero, A ;
Joo, S ;
Vannappagari, V .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (04) :350-353
[25]   Sildenafil, a novel effective oral therapy for male erectile dysfunction [J].
Boolell, M ;
GepiAttee, S ;
Gingell, JC ;
Allen, MJ .
BRITISH JOURNAL OF UROLOGY, 1996, 78 (02) :257-261
[26]   Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical "aging male" symptoms? Results of the "Cologne male survey [J].
Braun, MH ;
Sommer, F ;
Haupt, G ;
Mathers, MJ ;
Reifenrath, B ;
Engelmann, UH .
EUROPEAN UROLOGY, 2003, 44 (05) :588-594
[27]  
Burls A, 2001, BRIT J GEN PRACT, V51, P1004
[28]   Nitric oxide in the penis: Physiology and pathology [J].
Burnett, AL .
JOURNAL OF UROLOGY, 1997, 157 (01) :320-324
[29]   The efficacy and safety of tadalafil: an update [J].
Carson, CC ;
Rajfer, J ;
Eardley, I ;
Carrier, S ;
Denne, JS ;
Walker, DJ ;
Shen, W ;
Cordell, WH .
BJU INTERNATIONAL, 2004, 93 (09) :1276-1281
[30]   The efficacy of sildenafil citrate (Viagra®) in clinical populations:: An update [J].
Carson, CC ;
Burnett, AL ;
Levine, LA ;
Nehra, A .
UROLOGY, 2002, 60 (2B) :12-27